Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 17, 2021

View Archived Issues

Cell-penetrating peptides developed to target STAT3 for antitumor effects

Enfortumab vedotin shows promise for treating patients with advanced urothelial cancer

CXCR7 as a novel therapeutic target for myocardial infarction

Diffusion completes phase Ib study of TSC in hospitalized COVID-19 patients with hypoxemia

First patient dosed in phase I study of ADG-20 monoclonal antibody against COVID-19

Recce and Fiona Stanley Hospital to assess RECCE-327 as topical spray-on antibiotic

Cytocom updates IND application for CYTO-205 as treatment of COVID-19

ReAlta initiates dosing in phase I healthy volunteers study of RLS-0071

bluebird bio temporary suspends studies of LentiGlobin gene therapy for SCD

ApoEe4 plays an isoform-specific role in tau pathology

Updated phase I/II data for ABO-101 gene therapy in patients with MPS IIIB

Sun Pharma Advanced Research describes new SERDs

Mice can inherit paternal depression via sperm microRNA

Heptamer small guide RNA promotes M1 shift in TAMs: a potential new modality for myeloma treatment

Small molecule targeting ER stress-responsive chaperones suppresses abnormal tau protein aggregation

AT-GTX-501 slows motor and language function decline in vLINCL6

Bayer presents antibody-drug conjugates with NAMPT inhibitors

Lenvatinib plus pembrolizumab improves survival in patients with advanced RCC

New STING agonists patented by Shanghai Jemincare Pharmaceuticals, Jiangxi Jemincare Group

New coagulation factor XIa inhibitors identified at Medshine Discovery

AstraZeneca discovers PARP-1 inhibitors

FDA approves label expansion in chronic heart failure for Entresto

Incannex expands development of IHL-675A to include inflammatory bowel disease

Pfizer begins pivotal phase II study of elranatamab in relapsed or refractory multiple myeloma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Hippocratic loath? ‘Harm’ threat from ACIP’s proposed HBV shift
BioWorld
Individual liberty and choice vs. wider public health became one predictable hinge upon which swung the often-acerbic debates at the CDC’s Advisory Committee for...
Høeg appointment as acting CDER director tied to vaccine strategy?
BioWorld
After a more than 13-year period of stability with Janet Woodcock as the head of CDER, with Patrizia Cavazzoni taking charge during the next four years of former...
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...